Pharmaceutical regulatory data, drug approvals & compliance tracking
Home › Drug Approvals › Immunology
Access detailed information about immunology drug approvals. FDA News aggregates data from multiple verified sources to provide actionable insights. Our methodology combines automated data collection with expert curation to ensure high-quality, reliable information. Each data point is verified against multiple sources before publication.
Historical data is available for trend analysis, allowing users to identify patterns and forecast future developments. The platform supports custom date ranges and filtering options for deeper analysis. Professional analysts frequently cite our data in market reports and strategic presentations. Our methodology has been validated by independent auditors and meets industry-standard accuracy requirements.
Updated regularly with the latest available data. Bookmark this page for easy access to current information. Sign up for our newsletter to receive updates directly.
| Drug Name | Manufacturer | Approval Date | Indication | Type |
|---|---|---|---|---|
| Immuxumab | PharmaCo A | Mar 2026 | Advanced immunology | Biologic |
| Immutinib | PharmaCo B | Jan 2026 | Relapsed immunology | Small molecule |
| Immulizumab | PharmaCo C | Nov 2025 | Moderate immunology | Monoclonal Ab |
| Immustat | PharmaCo D | Sep 2025 | Chronic immunology | Oral |
| Immuparin | PharmaCo E | Jul 2025 | Acute immunology | Injectable |
Data updated continuously. Last refresh: May 11, 2026 14:30 UTC.
